(2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094.
(2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174.
(2022). Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. Nat Commun, 13, 5126. http://doi.org/10.1038/s41467-022-32310-3.
(2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021.
(2022). Transparency of high-dimensional propensity score analyses: guidance for diagnostics and reporting. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5412.
(2018). Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. BMJ Open. http://doi.org/10.1136/bmjopen-2017-019475.
(2019). Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol. http://doi.org/10.2147/clep.s181242.
(2020). Real world effects of COPD medications: a cohort study with validation against RCT results. Eur Respir J. http://doi.org/10.1183/13993003.01586-2020.
(2021). Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. Health Technol Assess. http://doi.org/10.3310/hta25510.
(2021). The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes Obes Metab. http://doi.org/10.1111/dom.14494.